Pfizer Gets $1.5bn for Monthly Weight-Loss Drug
Pfizer Gets $1.5bn for Monthly Weight-Loss Drug
Pfizer Gets $1.5bn for Monthly Weight-Loss Drug
Key points
اہم نکات
मुख्य बातें
- $1.5 billion from Blackstone will fund Pfizer's monthly weight-loss shot berobenatide through 2028, in a deal announced on November 11.
- Blackstone gets milestone payments only if US regulators approve monthly dosing and sales hit targets, but no ownership or rights in the drug, and Pfizer keeps full control of the programme.
- Pfizer picked up berobenatide in its up-to-$10 billion Metsera takeover and plans more than 20 obesity trials in 2026, including 10 Phase 3 studies of the shot.
- $1.5 billion from Blackstone will fund Pfizer's monthly weight-loss shot berobenatide through 2028, in a deal announced on November 11.
- Blackstone gets milestone payments only if US regulators approve monthly dosing and sales hit targets, but no ownership or rights in the drug, and Pfizer keeps full control of the programme.
- Pfizer picked up berobenatide in its up-to-$10 billion Metsera takeover and plans more than 20 obesity trials in 2026, including 10 Phase 3 studies of the shot.
- $1.5 billion from Blackstone will fund Pfizer's monthly weight-loss shot berobenatide through 2028, in a deal announced on November 11.
- Blackstone gets milestone payments only if US regulators approve monthly dosing and sales hit targets, but no ownership or rights in the drug, and Pfizer keeps full control of the programme.
- Pfizer picked up berobenatide in its up-to-$10 billion Metsera takeover and plans more than 20 obesity trials in 2026, including 10 Phase 3 studies of the shot.
$1.5 billion from Blackstone will fund Pfizer's monthly weight-loss shot berobenatide through 2028, in a deal announced on November 11. Blackstone gets milestone payments only if US regulators approve monthly dosing and sales hit targets, but no ownership or rights in the drug, and Pfizer keeps full control of the programme. Pfizer picked up berobenatide in its up-to-$10 billion Metsera takeover and plans more than 20 obesity trials in 2026, including 10 Phase 3 studies of the shot.
$1.5 billion from Blackstone will fund Pfizer's monthly weight-loss shot berobenatide through 2028, in a deal announced on November 11. Blackstone gets milestone payments only if US regulators approve monthly dosing and sales hit targets, but no ownership or rights in the drug, and Pfizer keeps full control of the programme. Pfizer picked up berobenatide in its up-to-$10 billion Metsera takeover and plans more than 20 obesity trials in 2026, including 10 Phase 3 studies of the shot.
$1.5 billion from Blackstone will fund Pfizer's monthly weight-loss shot berobenatide through 2028, in a deal announced on November 11. Blackstone gets milestone payments only if US regulators approve monthly dosing and sales hit targets, but no ownership or rights in the drug, and Pfizer keeps full control of the programme. Pfizer picked up berobenatide in its up-to-$10 billion Metsera takeover and plans more than 20 obesity trials in 2026, including 10 Phase 3 studies of the shot.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।